Rezdiffra (resmetirom) has been approved by the FDA of the USA for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to...
Study describes a novel mechanism involved in progression of non-alcoholic fatty liver disease and highlights protein Mitofusin 2 as having the potential to be...